TNGX Tango Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TNGX

Price (delayed)

$24.45

Market cap

$4.12B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.85

Enterprise value

$3.81B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 38

BCTG Acquisition Corp. (“BCTG”) is a Delaware corporation formed for the purpose of entering into a business combination with one or more businesses in the biotechnology sector, with a focus ...

Highlights
The equity has soared by 162% QoQ
Tango Therapeutics's quick ratio has soared by 88% from the previous quarter
The revenue has soared by 121% YoY but it fell by 6% QoQ
The gross profit has surged by 121% year-on-year but it has declined by 6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology

Key stats

What are the main financial stats of TNGX

TNGX stock price

How has the Tango Therapeutics stock price performed over time
Intraday
-4.23%
1 week
4.71%
1 month
2.39%
1 year
235.85%
YTD
175.96%
QTD
-21.79%

Financial performance

How have Tango Therapeutics's revenue and profit performed over time
Revenue
$53.81M
Gross profit
$53.81M
Operating income
-$136.35M
Net income
-$123.72M
Gross margin
100%
Net margin
-229.9%
The revenue has soared by 121% YoY but it fell by 6% QoQ
The gross profit has surged by 121% year-on-year but it has declined by 6% since the previous quarter
The net margin has soared by 62% YoY but it has contracted by 22% from the previous quarter
The operating margin has soared by 61% year-on-year but it is down by 23% since the previous quarter

Price vs fundamentals

How does TNGX's price correlate with its fundamentals

Growth

What is Tango Therapeutics's growth rate over time

Valuation

What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
3.45
P/S
68.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.78
Tango Therapeutics's EPS has increased by 36% YoY but it has decreased by 2.4% QoQ
The equity has soared by 162% QoQ
The stock's P/B is 32% less than its last 4 quarters average of 5.3 but 16% more than its 5-year quarterly average of 3.1
The revenue has soared by 121% YoY but it fell by 6% QoQ
TNGX's price to sales (P/S) is 67% higher than its last 4 quarters average of 42.6

Efficiency

How efficient is Tango Therapeutics business performance
The ROE has soared by 68% year-on-year and by 38% since the previous quarter
Tango Therapeutics's return on sales has surged by 62% YoY but it has decreased by 22% QoQ
The ROA has soared by 53% year-on-year and by 30% since the previous quarter
TNGX's ROIC is up by 46% YoY and by 27% from the previous quarter

Dividends

What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNGX.

Financial health

How did Tango Therapeutics financials performed over time
The total assets has soared by 146% from the previous quarter
Tango Therapeutics's quick ratio has soared by 88% from the previous quarter
The debt is 97% less than the equity
The equity has soared by 162% QoQ
The debt to equity has dropped by 88% year-on-year and by 63% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.